New combo therapy aims to unmask lymphoma cells and boost immune attack
NCT ID NCT05507541
First seen Apr 28, 2026 · Last updated Jun 19, 2026 · Updated 14 times
Summary
This phase 2 trial tests a combination of two drugs—TTI-622 and pembrolizumab—in about 10 adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune system, while pembrolizumab helps immune cells attack the cancer. The study first finds the safest dose of TTI-622 when given with pembrolizumab, then checks how well the combination shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.